Diethylcarbamazine as potential treatment of COVID-19 lung fibrosis

Diethylcarbamazine, the antiparasitic drug, also possesses anti-inflammatory and immunomodulatory activities. The anti-fibrotic activity of diethylcarbamazine makes it a potential candidate to treat coronavirus disease 2019 (COVID-19)-related pulmonary fibrosis. Experimental and clinical studies sho...

Descripción completa

Detalles Bibliográficos
Autores principales: Medina-De la Garza, Carlos Eduardo, Salvador Flores-Torres, Armando, García-Hernández, Marisela, de los Ángeles Castro-Corona, María
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd. 2022
Materias:
Correspondence
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8788098/
https://www.ncbi.nlm.nih.gov/pubmed/35095174
http://dx.doi.org/10.1016/j.mehy.2022.110774
_version_ 1784639486738563072
author Medina-De la Garza, Carlos Eduardo
Salvador Flores-Torres, Armando
García-Hernández, Marisela
de los Ángeles Castro-Corona, María
author_facet Medina-De la Garza, Carlos Eduardo
Salvador Flores-Torres, Armando
García-Hernández, Marisela
de los Ángeles Castro-Corona, María
author_sort Medina-De la Garza, Carlos Eduardo
collection PubMed
description Diethylcarbamazine, the antiparasitic drug, also possesses anti-inflammatory and immunomodulatory activities. The anti-fibrotic activity of diethylcarbamazine makes it a potential candidate to treat coronavirus disease 2019 (COVID-19)-related pulmonary fibrosis. Experimental and clinical studies should assess this possible effect.
format Online
Article
Text
id pubmed-8788098
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier Ltd.
record_format MEDLINE/PubMed
spelling pubmed-87880982022-01-25 Diethylcarbamazine as potential treatment of COVID-19 lung fibrosis Medina-De la Garza, Carlos Eduardo Salvador Flores-Torres, Armando García-Hernández, Marisela de los Ángeles Castro-Corona, María Med Hypotheses Correspondence Diethylcarbamazine, the antiparasitic drug, also possesses anti-inflammatory and immunomodulatory activities. The anti-fibrotic activity of diethylcarbamazine makes it a potential candidate to treat coronavirus disease 2019 (COVID-19)-related pulmonary fibrosis. Experimental and clinical studies should assess this possible effect. Elsevier Ltd. 2022-03 2022-01-25 /pmc/articles/PMC8788098/ /pubmed/35095174 http://dx.doi.org/10.1016/j.mehy.2022.110774 Text en © 2022 Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Correspondence
Medina-De la Garza, Carlos Eduardo
Salvador Flores-Torres, Armando
García-Hernández, Marisela
de los Ángeles Castro-Corona, María
Diethylcarbamazine as potential treatment of COVID-19 lung fibrosis
title Diethylcarbamazine as potential treatment of COVID-19 lung fibrosis
title_full Diethylcarbamazine as potential treatment of COVID-19 lung fibrosis
title_fullStr Diethylcarbamazine as potential treatment of COVID-19 lung fibrosis
title_full_unstemmed Diethylcarbamazine as potential treatment of COVID-19 lung fibrosis
title_short Diethylcarbamazine as potential treatment of COVID-19 lung fibrosis
title_sort diethylcarbamazine as potential treatment of covid-19 lung fibrosis
topic Correspondence
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8788098/
https://www.ncbi.nlm.nih.gov/pubmed/35095174
http://dx.doi.org/10.1016/j.mehy.2022.110774
work_keys_str_mv AT medinadelagarzacarloseduardo diethylcarbamazineaspotentialtreatmentofcovid19lungfibrosis
AT salvadorflorestorresarmando diethylcarbamazineaspotentialtreatmentofcovid19lungfibrosis
AT garciahernandezmarisela diethylcarbamazineaspotentialtreatmentofcovid19lungfibrosis
AT delosangelescastrocoronamaria diethylcarbamazineaspotentialtreatmentofcovid19lungfibrosis

Ejemplares similares